Physician profile
Paul L Wolfe
NPI 1710983184
$1,184.31
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,103 · 2020: $81.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $197.52 | 2019-2020 | |
| Amgen INC. | $176.57 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $140.63 | 2019-2020 | |
| Pfizer INC. | $116.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.05 | 2019-2020 | |
| Astellas Pharma US INC | $78.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $77.15 | 2019 | |
| Sunovion Pharmaceuticals INC. | $74.37 | 2019 | |
| Novo Nordisk INC | $61.11 | 2019 | |
| Merck Sharp & Dohme LLC | $34.94 | 2019 | |
| Sanofi-Aventis U.S. LLC | $30.44 | 2019-2020 | |
| Amarin Pharma, INC. | $27.08 | 2019 | |
| Lilly USA, LLC | $22.78 | 2019 | |
| Genentech USA, INC. | $15.06 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.92 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $12.19 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.89 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Wolfe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.